Abbott, NEA Show Medtech Deals Still Have Some Pop
This article was originally published in Start Up
Executive Summary
With a paucity of VC firms willing to invest in medtech companies, strategic players are being called upon to assume larger, more active roles in the process of starting and funding the start-ups that they may someday acquire. Last month, Abbott made a forceful move into the electrophysiology space with a trio of deals involving companies backed by New Enterprise Associates.
You may also be interested in...
New NEA Fund Could Bring $1 Billion To Health Care
Following two years of strong exits from biopharma and medtech investment, New Enterprise Associates raised over $3.1 billion for its 15th fund raising. The new pool of capital consists of $2.8 billion for a traditional venture fund – the fourth consecutive fund to top $2.5 billion – and a $350 million “Opportunity Fund” that will be co-invested with the new and prior fund in late-stage growth equity deals.
Device/Diagnostics Quarterly Deal Statistics, Q4 2014
Q4 device financing reached $902 million versus Q3’s $734 million, while device M&A dollar volume increased $19 billion, from Q3’s $4.9 billion. Diagnostics companies raised $750 million, an 85% rise over the previous quarter’s $405 million; although diagnostics M&A totaled just $1 billion, it was the most deal-active quarter of 2014 with 11 transactions.
Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.